PHLDA1

Across TCGA pan-cancer cohorts, PHLDA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHLDA1 data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHLDA1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHLDA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where PHLDA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.167	0.550	.005	20	view →
UCEC	OS	Tertile	All	1.000	0.840	.004	12	view →
CCRCC	OS	Tertile	IV	0.830	0.198	.024	6	view →
LUAD	DFS	Quartile	III,IV	0.658	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHLDA1–PDAC (DFS)

Open the PDAC breakdown →